default author photo

Rafael Fonseca

Mayo Clinic

200 First Street SW

Rochester, MN (507) 284-2511 55905

United States

SCHOLARLY PAPERS

3

DOWNLOADS

247

TOTAL CITATIONS

3

Scholarly Papers (3)

1.

Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: A prospective cohort study

Number of pages: 72 Posted: 03 Mar 2022
Harvard University - Center for Prevention of Progression of Blood Cancers, Harvard University - Department of Medical Oncology, Harvard University - Department of Medical Oncology, Harvard University - Department of Biostatistics and Computational Biology, Harvard University - Department of Medical Oncology, Harvard University - Department of Medical Oncology, Harvard University - Department of Medical Oncology, Harvard University - Department of Medical Oncology, The Binding Site Inc., The Binding Site Inc., Cornell University - Weill Cornell Medicine, Harvard University - Department of Medical Oncology, Mayo Clinic - Alix School of Medicine, Harvard University - Department of Medical Oncology, Harvard University - Department of Medical Oncology, Harvard University - Department of Medical Oncology, Harvard University - Department of Medical Oncology, Harvard University - Department of Medical Oncology, The Binding Site Group Ltd., The Binding Site Group Ltd., Harvard University - Department of Medical Oncology, Mayo Clinic, City of Hope - City of Hope Cancer Center, Johns Hopkins University - Johns Hopkins Hospital, Mayo Clinic, Harvard University - Harvard Medical School, Harvard University - Harvard Medical School, Harvard University - Department of Biostatistics and Computational Biology, Harvard University - Dana-Farber Cancer Institute, Harvard University - Harvard Medical School, Harvard University - Department of Medical Oncology and Harvard University - Department of Medical Oncology
Downloads 159 (474,889)
Citation 3

Abstract:

Loading...

Multiple myeloma, monoclonal gammopathy, cancer screening, mass spectrometry

2.

FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated with CAR-T

Number of pages: 39 Posted: 08 Sep 2025
Mayo Clinic, Stanford Medicine, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Analysis Group, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 45 (1,121,190)

Abstract:

Loading...

CAR-T Cell Therapy, second primary malignancies, adverse events, Risk factors, Multiple myeloma, lymphoma, Leukemia

3.

Dose delays and treatment interruptions secondary to ocular toxicity from BMCA-directed antibody drug conjugate therapy in relapsed multiple myeloma

Number of pages: 22 Posted: 27 Aug 2025 Last Revised: 07 Feb 2026
affiliation not provided to SSRN, Mayo Clinic, Mayo Clinic, Mayo Clinic, affiliation not provided to SSRN, affiliation not provided to SSRN, Mayo Clinic, New York University (NYU) - Grossman School of Medicine, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic and Mayo Clinic - Division of Hematology
Downloads 43 (1,145,425)

Abstract:

Loading...

B-cell maturation antigen, antibody drug conjugates, Multiple myeloma, monoclonal gammopathy, keratopathy, adverse effects